Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Saurabh Zanwar, Morie A Gertz, Eli Muchtar, Francis K Buadi, Taxiarchis Kourelis, Wilson Gonsalves, Ronald S Go, Suzanne Hayman, Prashant Kapoor, Moritz Binder, Joselle Cook, David Dingli, Nelson Leung, Yi Lin, Rahma Warsame, Amie Fonder, Miriam Hobbs, Yi Lisa Hwa, Robert A Kyle, S Vincent Rajkumar, Shaji Kumar, Angela Dispenzieri
No abstract text is available yet for this article.
April 9, 2024: Leukemia
#2
RANDOMIZED CONTROLLED TRIAL
John Devin Peipert, Fengmin Zhao, Ju-Whei Lee, Shu-En Shen, Edward Ip, Nathaniel O'Connell, Ruth C Carlos, Noah Graham, Mary Lou Smith, Ilana F Gareen, Pamela J Raper, Matthias Weiss, Shaji K Kumar, S Vincent Rajkumar, David Cella, Robert Gray, Lynne I Wagner
IMPORTANCE: There is substantial interest in capturing cancer treatment tolerability from the patient's perspective using patient-reported outcomes (PROs). OBJECTIVE: To examine whether a PRO question, item 5 from the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale (GP5), was associated with early treatment discontinuation (ETD) due to adverse events. DESIGN, SETTING, AND PARTICIPANTS: This prospective survey study was conducted from February to April 2023...
March 4, 2024: JAMA Network Open
#3
JOURNAL ARTICLE
Utkarsh Goel, Charalampos Charalampous, Prashant Kapoor, Moritz Binder, Francis K Buadi, David Dingli, Angela Dispenzieri, Amie Fonder, Morie A Gertz, Wilson I Gonsalves, Suzanne R Hayman, Miriam A Hobbs, Yi L Hwa, Taxiarchis Kourelis, Martha Q Lacy, Nelson Leung, Yi Lin, Rahma M Warsame, Robert A Kyle, S Vincent Rajkumar, Shaji K Kumar
Refractoriness to lenalidomide is an important factor determining the choice of therapy at first relapse in multiple myeloma (MM). It remains debatable if resistance to lenalidomide varies among MM refractory to standard doses vs low dose maintenance doses. In this study, we assessed the outcomes with subsequent therapies in patients with MM refractory to standard dose vs low dose lenalidomide. We retrospectively reviewed all patients with MM at our institution who received first line therapy with lenalidomide containing regimens, and assessed progression free survival (PFS) and overall survival for these patients for second line therapy, and with lenalidomide retreatment...
March 26, 2024: Blood Cancer Journal
#4
JOURNAL ARTICLE
Fieke W Hoff, Rahul Banerjee, Adeel M Khan, Georgia McCaughan, Bo Wang, Xiaoliang Wang, James Roose, Larry D Anderson, Andrew J Cowan, S Vincent Rajkumar, Gurbakhash Kaur
Induction regimens for multiple myeloma (MM) commonly include bortezomib, which has typically been administered twice weekly despite studies demonstrating comparable efficacy and less peripheral neuropathy (PN) with once-weekly bortezomib. We aimed to analyze the real-world prevalence and efficacy of once-weekly versus twice-weekly bortezomib regimens in newly diagnosed MM. We analyzed 2497 US patients aged 18-70 years treated with commercial first-line bortezomib using nationwide Flatiron Health electronic health record-derived data, including 910 (36...
March 22, 2024: Blood Cancer Journal
#5
JOURNAL ARTICLE
Nadine Abdallah, Thomas E Witzig, Shaji K Kumar, Martha Q Lacy, Suzanne R Hayman, Angela Dispenzieri, Vivek Roy, Morie A Gertz, P Leif Bergsagel, S Vincent Rajkumar
No abstract text is available yet for this article.
February 28, 2024: Leukemia
#6
REVIEW
Geraint H Jones, Colin Snodgrass, Cecilia Tubiana, Michael Küppers, Hideyo Kawakita, Luisa M Lara, Jessica Agarwal, Nicolas André, Nicholas Attree, Uli Auster, Stefano Bagnulo, Michele Bannister, Arnaud Beth, Neil Bowles, Andrew Coates, Luigi Colangeli, Carlos Corral van Damme, Vania Da Deppo, Johan De Keyser, Vincenzo Della Corte, Niklas Edberg, Mohamed Ramy El-Maarry, Sara Faggi, Marco Fulle, Ryu Funase, Marina Galand, Charlotte Goetz, Olivier Groussin, Aurélie Guilbert-Lepoutre, Pierre Henri, Satoshi Kasahara, Akos Kereszturi, Mark Kidger, Matthew Knight, Rosita Kokotanekova, Ivana Kolmasova, Konrad Kossacki, Ekkehard Kührt, Yuna Kwon, Fiorangela La Forgia, Anny-Chantal Levasseur-Regourd, Manuela Lippi, Andrea Longobardo, Raphael Marschall, Marek Morawski, Olga Muñoz, Antti Näsilä, Hans Nilsson, Cyrielle Opitom, Mihkel Pajusalu, Antoine Pommerol, Lubomir Prech, Nicola Rando, Francesco Ratti, Hanna Rothkaehl, Alessandra Rotundi, Martin Rubin, Naoya Sakatani, Joan Pau Sánchez, Cyril Simon Wedlund, Anamarija Stankov, Nicolas Thomas, Imre Toth, Geronimo Villanueva, Jean-Baptiste Vincent, Martin Volwerk, Peter Wurz, Arno Wielders, Kazuo Yoshioka, Konrad Aleksiejuk, Fernando Alvarez, Carine Amoros, Shahid Aslam, Barbara Atamaniuk, Jędrzej Baran, Tomasz Barciński, Thomas Beck, Thomas Behnke, Martin Berglund, Ivano Bertini, Marcin Bieda, Piotr Binczyk, Martin-Diego Busch, Andrei Cacovean, Maria Teresa Capria, Chris Carr, José María Castro Marín, Matteo Ceriotti, Paolo Chioetto, Agata Chuchra-Konrad, Lorenzo Cocola, Fabrice Colin, Chiaki Crews, Victoria Cripps, Emanuele Cupido, Alberto Dassatti, Björn J R Davidsson, Thierry De Roche, Jan Deca, Simone Del Togno, Frederik Dhooghe, Kerri Donaldson Hanna, Anders Eriksson, Andrey Fedorov, Estela Fernández-Valenzuela, Stefano Ferretti, Johan Floriot, Fabio Frassetto, Jesper Fredriksson, Philippe Garnier, Dorota Gaweł, Vincent Génot, Thomas Gerber, Karl-Heinz Glassmeier, Mikael Granvik, Benjamin Grison, Herbert Gunell, Tedjani Hachemi, Christian Hagen, Rajkumar Hajra, Yuki Harada, Johann Hasiba, Nico Haslebacher, Miguel Luis Herranz De La Revilla, Daniel Hestroffer, Tilak Hewagama, Carrie Holt, Stubbe Hviid, Iaroslav Iakubivskyi, Laura Inno, Patrick Irwin, Stavro Ivanovski, Jiri Jansky, Irmgard Jernej, Harald Jeszenszky, Jaime Jimenéz, Laurent Jorda, Mihkel Kama, Shingo Kameda, Michael S P Kelley, Kamil Klepacki, Tomáš Kohout, Hirotsugu Kojima, Tomasz Kowalski, Masaki Kuwabara, Michal Ladno, Gunter Laky, Helmut Lammer, Radek Lan, Benoit Lavraud, Monica Lazzarin, Olivier Le Duff, Qiu-Mei Lee, Cezary Lesniak, Zoe Lewis, Zhong-Yi Lin, Tim Lister, Stephen Lowry, Werner Magnes, Johannes Markkanen, Ignacio Martinez Navajas, Zita Martins, Ayako Matsuoka, Barbara Matyjasiak, Christian Mazelle, Elena Mazzotta Epifani, Mirko Meier, Harald Michaelis, Marco Micheli, Alessandra Migliorini, Aude-Lyse Millet, Fernando Moreno, Stefano Mottola, Bruno Moutounaick, Karri Muinonen, Daniel R Müller, Go Murakami, Naofumi Murata, Kamil Myszka, Shintaro Nakajima, Zoltan Nemeth, Artiom Nikolajev, Simone Nordera, Dan Ohlsson, Aire Olesk, Harald Ottacher, Naoya Ozaki, Christophe Oziol, Manish Patel, Aditya Savio Paul, Antti Penttilä, Claudio Pernechele, Joakim Peterson, Enrico Petraglio, Alice Maria Piccirillo, Ferdinand Plaschke, Szymon Polak, Frank Postberg, Herman Proosa, Silvia Protopapa, Walter Puccio, Sylvain Ranvier, Sean Raymond, Ingo Richter, Martin Rieder, Roberto Rigamonti, Irene Ruiz Rodriguez, Ondrej Santolik, Takahiro Sasaki, Rolf Schrödter, Katherine Shirley, Andris Slavinskis, Balint Sodor, Jan Soucek, Peter Stephenson, Linus Stöckli, Paweł Szewczyk, Gabor Troznai, Ludek Uhlir, Naoto Usami, Aris Valavanoglou, Jakub Vaverka, Wei Wang, Xiao-Dong Wang, Gaëtan Wattieaux, Martin Wieser, Sebastian Wolf, Hajime Yano, Ichiro Yoshikawa, Vladimir Zakharov, Tomasz Zawistowski, Paola Zuppella, Giovanna Rinaldi, Hantao Ji
Here we describe the novel, multi-point Comet Interceptor mission. It is dedicated to the exploration of a little-processed long-period comet, possibly entering the inner Solar System for the first time, or to encounter an interstellar object originating at another star. The objectives of the mission are to address the following questions: What are the surface composition, shape, morphology, and structure of the target object? What is the composition of the gas and dust in the coma, its connection to the nucleus, and the nature of its interaction with the solar wind? The mission was proposed to the European Space Agency in 2018, and formally adopted by the agency in June 2022, for launch in 2029 together with the Ariel mission...
2024: Space Science Reviews
#7
JOURNAL ARTICLE
Nadine H Abdallah, Arjun Lakshman, Shaji K Kumar, Joselle Cook, Moritz Binder, Prashant Kapoor, Angela Dispenzieri, Morie A Gertz, Martha Q Lacy, Suzanne R Hayman, Francis K Buadi, David Dingli, Yi Lin, Taxiarchis Kourelis, Rahma Warsame, Leif Bergsagel, S Vincent Rajkumar
The approach to patients with high-risk smoldering multiple myeloma (SMM) varies among clinicians; while some advocate early intervention, others reserve treatment at progression to multiple myeloma (MM). We aimed to describe the myeloma-defining events (MDEs) and clinical presentations leading to MM diagnosis among SMM patients seen at our institution. We included 406 patients diagnosed with SMM between 2013-2022, seen at Mayo Clinic, Rochester, MN. The 2018 Mayo 20/2/20 criteria were used for risk stratification...
January 17, 2024: Blood Cancer Journal
#8
REVIEW
S Vincent Rajkumar, P Leif Bergsagel, Shaji Kumar
Smoldering multiple myeloma (SMM) is an intermediate clinical stage in the spectrum of monoclonal plasma cell disorders. It represents a heterogeneous clinically defined condition in which some patients (approximately 50%) have monoclonal gammopathy of undetermined significance (premalignancy), and some (approximately 50%) have multiple myeloma (biologic malignancy). Using specific prognostic factors, patients with SMM, in whom malignant transformation has already likely occurred, can be identified. These patients are considered to have high-risk SMM...
December 28, 2023: Hematology/oncology Clinics of North America
#9
JOURNAL ARTICLE
Sarah Goldman-Mazur, Alissa Visram, S Vincent Rajkumar, Prashant Kapoor, Angela Dispenzieri, Martha Q Lacy, Morie A Gertz, Francis K Buadi, Suzanne R Hayman, David Dingli, Taxiarchis Kourelis, Wilson Gonsalves, Rahma Warsame, Eli Muchtar, Nelson Leung, Robert A Kyle, Shaji K Kumar
In multiple myeloma (MM) significant variation in progression-free survival (PFS) and overall survival (OS) is observed. We examined the outcomes of 1557 MM patients stratified into short (<2 years), medium (between 2 and 5 years) and long (>5 years) PFS. Short PFS occurred in 758 patients (48.7%), medium in 561 patients (36.2%), and long in 238 patients (15.3%). Median post-progression PFS was 9.2 months (95% CI: 8.1-11.0) in the short PFS and 33.1 months (95% CI: 29.0-42.1; P < .001) in the long PFS group...
November 27, 2023: Clinical Lymphoma, Myeloma & Leukemia
#10
JOURNAL ARTICLE
Hagop Kantarjian, Amer M Zeidan, Amir T Fathi, Eytan Stein, Vincent Rajkumar, Ayalew Tefferi
Today, approximately 50% of patients eligible for Medicare have opted for Medicare Advantage as their primary coverage. Whereas Medicare Advantage is a reasonable option for healthy senior Americans, issues arise once they have serious or chronic medical problems, which are prevalent among older Americans. This review details the pros and cons of standard Medicare vs Medicare Advantage. The authors recommend considering standard Medicare as a better form of insurance coverage. In addition, patients should also enroll in Medicare Part D to get prescription drug coverage; buy a supplemental MediGap policy; and buy additional coverage for hearing, vision, and dental care...
November 27, 2023: Mayo Clinic Proceedings
#11
JOURNAL ARTICLE
Nadine H Abdallah, Hiroki Nagayama, Naoki Takahashi, Wilson Gonsalves, Amie Fonder, Angela Dispenzieri, David Dingli, Francis K Buadi, Martha Q Lacy, Miriam Hobbs, Morie A Gertz, Moritz Binder, Prashant Kapoor, Rahma Warsame, Suzanne R Hayman, Taxiarchis Kourelis, Yi L Hwa, Yi Lin, Robert A Kyle, S Vincent Rajkumar, Stephen M Broski, Shaji K Kumar
Measures of muscle and adipose tissue mass have been associated with outcomes in several malignancies, but studies in multiple myeloma (MM) are inconsistent. The aim of this study was to evaluate the association between muscle and fat areas and radiodensity, and overall survival (OS) in patients with newly diagnosed MM. We included 341 patients diagnosed with MM from 2010-2019 who had an 18 F-fluorodeoxyglucose positron emission tomography/computed tomography at diagnosis. A cross-sectional image at the third lumbar vertebrae was segmented into muscle and fat components...
December 12, 2023: Blood Cancer Journal
#12
EDITORIAL
Tyler B Sandahl, S Vincent Rajkumar
No abstract text is available yet for this article.
December 2023: Mayo Clinic Proceedings
#13
JOURNAL ARTICLE
Paul G Richardson, Thierry Facon, Christopher P Venner, Nizar J Bahlis, Fritz Offner, Darrell White, Lionel Karlin, Lotfi Benboubker, Eric Voog, Sung-Soo Yoon, Kenshi Suzuki, Hirohiko Shibayama, Xiaoquan Zhang, Miguel Villarreal, Philip Twumasi-Ankrah, Richard Labotka, Robert M Rifkin, Sagar Lonial, Shaji K Kumar, S Vincent Rajkumar, Philippe Moreau
Deeper responses are associated with longer survival in multiple myeloma (MM); however, limited data exist on the impact of response kinetics on outcomes. We investigated progression-free survival (PFS) and duration of response (DOR) by response depth and in early (best confirmed response 0-4 months; n = 424) versus late responders (best confirmed response >4 months; n = 281). Newly diagnosed patients enrolled in TOURMALINE-MM2 receiving ixazomib-lenalidomide-dexamethasone (IRd) ( n = 351) or placebo-Rd ( n = 354) were evaluated post hoc ...
November 2023: EJHaem
#14
REVIEW
Prashant Kapoor, S Vincent Rajkumar
Waldenström macroglobulinemia (WM) is a unique CD20+, B-cell non-Hodgkin lymphoma, characterized by lymphoplasmacytic infiltration of the bone marrow and circulating monoclonal immunoglobulin M. The clinical manifestations and outcomes of patients are highly variable. High-level evidence supports integration of monoclonal anti-CD20 antibody, rituximab, to the chemotherapy backbone to treat WM. However, its contemporary management has become more nuanced, with deeper understanding of the pathophysiology and incorporation of Bruton's tyrosine kinase (BTK) inhibitors to the treatment paradigm...
November 2023: Blood Reviews
#15
JOURNAL ARTICLE
Marie-France Gagnon, Sally M Midthun, James A Fangel, Cynthia M Schuh, Ivy M Luoma, Kathryn E Pearce, Reid G Meyer, Sikander Ailawadhi, Mariano J Arribas, Esteban Braggio, Rafael Fonseca, S Vincent Rajkumar, Cinthya Zepeda-Mendoza, Xinjie Xu, Patricia T Greipp, Michael M Timm, Gregory E Otteson, Min Shi, Dragan Jevremovic, Horatiu Olteanu, Jess F Peterson, Rhett P Ketterling, Shaji Kumar, Linda B Baughn
OBJECTIVES: Fluorescence in situ hybridization (FISH) for plasma cell neoplasms (PCNs) requires plasma cell (PC) identification or purification strategies to optimize results. We compared the efficacy of cytoplasmic immunoglobulin FISH (cIg-FISH) and fluorescence-activated cell sorting FISH (FACS-FISH) in a clinical laboratory setting. METHODS: The FISH analysis results of 14,855 samples from individuals with a suspected PCN subjected to cytogenetic evaluation between 2019 and 2022 with cIg-FISH (n = 6917) or FACS-FISH (n = 7938) testing were analyzed...
September 2, 2023: American Journal of Clinical Pathology
#16
JOURNAL ARTICLE
Charalampos Charalampous, Utkarsh Goel, Prashant Kapoor, Moritz Binder, Francis K Buadi, Joselle Cook, David Dingli, Angela Dispenzieri, Amie L Fonder, Morie A Gertz, Wilson Gonsalves, Suzanne R Hayman, Miriam A Hobbs, Yi L Hwa, Taxiarchis Kourelis, Martha Q Lacy, Nelson Leung, Yi Lin, Rahma Warsame, Robert A Kyle, S Vincent Rajkumar, Shaji K Kumar
Patients with multiple myeloma (MM) who do not respond to initial therapy have worse outcomes than primary responders, and effective treatments are lacking in this population. However, the outcomes of primary refractory disease in the modern treatment era have not yet been studied. We reviewed patients with MM treated with triplet/quadruplet therapy at our institution to assess the incidence of primary refractory disease and the impact of salvage therapies in this population. We identified 1127 patients, of whom 1086 were evaluated for hematologic responses after 4 to 6 cycles...
August 22, 2023: Blood Advances
#17
JOURNAL ARTICLE
Udit Yadav, Shaji K Kumar, Linda B Baughn, Angela Dispenzieri, Patricia T Greipp, Rhett P Ketterling, Dragan Jevremovic, Francis K Buadi, David Dingli, Martha Q Lacy, Rafael Fonseca, P Leif Bergsagel, Sikander Ailawadhi, Vivek Roy, Ricardo D Parrondo, Taimur Sher, Suzanne R Hayman, Prashant Kapoor, Nelson Leung, Joselle Cook, Moritz Binder, Eli Muchtar, Rahma Warsame, Taxiarchis V Kourelis, Ronald S Go, Yi Lin, Abhishek Seth, Scott C Lester, William G Breen, Robert A Kyle, Morie A Gertz, S Vincent Rajkumar, Wilson I Gonsalves
Most patients with SBP progress to MM after definitive radiation therapy as their primary treatment. Whether the presence of high-risk (HR) cytogenetic abnormalities by FISH in the clonal plasma cells, obtained either directly from the diagnostic SBP tissue or the corresponding bone marrow examination at the time of diagnosis, is associated with a shorter time to progression (TTP) to MM is unknown. This study evaluated all patients diagnosed with SBP at the Mayo Clinic from January 2012 to July 2022. The presence of del(17p), t(14;16), t(4;14), or +1q (gain or amplification) by FISH in clonal plasma cells was defined as HR...
July 26, 2023: Blood
#18
Rita Alaggio, Catalina Amador, Ioannis Anagnostopoulos, Ayoma D Attygalle, Iguaracyra Barreto de Oliveira Araujo, Emilio Berti, Govind Bhagat, Anita Maria Borges, Daniel Boyer, Mariarita Calaminici, Amy Chadburn, John K C Chan, Wah Cheuk, Wee-Joo Chng, John K Choi, Shih-Sung Chuang, Sarah E Coupland, Magdalena Czader, Sandeep S Dave, Daphne de Jong, Arianna Di Napoli, Ming-Qing Du, Kojo S Elenitoba-Johnson, Judith Ferry, Julia Geyer, Dita Gratzinger, Joan Guitart, Sumeet Gujral, Marian Harris, Christine J Harrison, Sylvia Hartmann, Andreas Hochhaus, Patty M Jansen, Kennosuke Karube, Werner Kempf, Joseph Khoury, Hiroshi Kimura, Wolfram Klapper, Alexandra E Kovach, Shaji Kumar, Alexander J Lazar, Stefano Lazzi, Lorenzo Leoncini, Nelson Leung, Vasiliki Leventaki, Xiao-Qiu Li, Megan S Lim, Wei-Ping Liu, Abner Louissaint, Andrea Marcogliese, L Jeffrey Medeiros, Michael Michal, Roberto N Miranda, Christina Mitteldorf, Santiago Montes-Moreno, William Morice, Valentina Nardi, Kikkeri N Naresh, Yasodha Natkunam, Siok-Bian Ng, Ilske Oschlies, German Ott, Marie Parrens, Melissa Pulitzer, S Vincent Rajkumar, Andrew C Rawstron, Karen Rech, Andreas Rosenwald, Jonathan Said, Clémentine Sarkozy, Shahin Sayed, Caner Saygin, Anna Schuh, William Sewell, Reiner Siebert, Aliyah R Sohani, Ritsuro Suzuki, Reuben Tooze, Alexandra Traverse-Glehen, Francisco Vega, Beatrice Vergier, Ashutosh D Wechalekar, Brent Wood, Luc Xerri, Wenbin Xiao
No abstract text is available yet for this article.
September 2023: Leukemia
#19
JOURNAL ARTICLE
Saurabh Zanwar, Matthew Ho, Yi Lin, Prashant Kapoor, Moritz Binder, Francis K Buadi, Angela Dispenzieri, David Dingli, Amie Fonder, Morie A Gertz, Wilson Gonsalves, Suzanne R Hayman, Yi Hwa, Miriam Hobbs, Taxiarchis Kourelis, Martha Q Lacy, Nelson Leung, Eli Muchtar, Rahma Warsame, Dragan Jevremovic, Robert A Kyle, S Vincent Rajkumar, Shaji Kumar
Extramedullary multiple myeloma (EMM) can present either at initial diagnosis (de novo) or at disease relapse (secondary) and confers an aggressive clinical course. Limited data exist for choosing the optimal therapy for EMM and this remains an area of unmet clinical need. After excluding paraskeletal multiple myeloma and primary plasma cell leukemia, we identified 204 (68%) patients with secondary EMM and 95 (32%) with de novo EMM between January 01, 2000 and 31 December, 2021. The median overall survival (OS) was 0...
July 8, 2023: American Journal of Hematology
#20
REVIEW
Meletios A Dimopoulos, Giampaolo Merlini, Frank Bridoux, Nelson Leung, Joseph Mikhael, Simon J Harrison, Efstathios Kastritis, Laurent Garderet, Alessandro Gozzetti, Niels W C J van de Donk, Katja C Weisel, Ashraf Z Badros, Meral Beksac, Jens Hillengass, Mohamad Mohty, P Joy Ho, Ioannis Ntanasis-Stathopoulos, Maria-Victoria Mateos, Paul Richardson, Joan Blade, Philippe Moreau, Jesus San-Miguel, Nikhil Munshi, S Vincent Rajkumar, Brian G M Durie, Heinz Ludwig, Evangelos Terpos
Here, the International Myeloma Working Group (IMWG) updates its clinical practice recommendations for the management of multiple myeloma-related renal impairment on the basis of data published until Dec 31, 2022. All patients with multiple myeloma and renal impairment should have serum creatinine, estimated glomerular filtration rate, and free light chains (FLCs) measurements together with 24-h urine total protein, electrophoresis, and immunofixation. If non-selective proteinuria (mainly albuminuria) or involved serum FLCs value less than 500 mg/L is detected, then a renal biopsy is needed...
July 2023: Lancet Oncology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
